LILY VANZALEN: Open Payments
NPI 1376244376 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,752 in 71 payments from 33 companies in 2025. Trend: 2023 $127 · 2024 $652 · 2025 $1,752
Food & beverage: $1,752
| Company | Payments | Amount |
|---|---|---|
| TerSera Therapeutics LLC | 5 | $129 |
| Merck Sharp & Dohme LLC | 4 | $106 |
| Novartis Pharmaceuticals Corporation | 4 | $106 |
| Eisai Inc. | 4 | $104 |
| JAZZ PHARMACEUTICALS INC. | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $99 |
| Genentech USA, Inc. | 5 | $92 |
| Incyte Corporation | 3 | $80 |
| Amgen Inc. | 1 | $73 |
| Daiichi Sankyo Inc. | 3 | $71 |
Products named: KEYTRUDA, Lenvima, FRUZAQLA, Zoladex, Fabhalta, MONJUVI, BRUKINSA, OPDIVO.
Industry payments across MI — which companies pay providers there.
